- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05283564
Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy
August 22, 2023 updated by: Stanford University
A Pilot Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy (PVB-SABR)
The purpose of this research is to evaluate and determine the rate of successful administration of Percussive ventilation breathhold (PVB) to allow for more accurate radiotherapy for lung tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Primary Objective(s)
- To determine the rate of successful administration of the PVB-SABR in lung cancer patients.
- To determine the rate of successful administration of PVB in healthy volunteers for 5 minutes
Secondary Objective(s)
- To determine the rate of successful administration of PVB in healthy volunteers for 10 minutes as well as for patients' successfully completing the technique for 5 and 10 minutes.
- To collect exploratory clinical (both arms) and dosimetric data from lung cancer patients using PVB-SABR.
- To collect patient-reported data on hospital-associated anxiety, motivation to learn the technique from the educational materials, and subjective evaluation of those materials
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aneesh Swamy
- Phone Number: 650-725-2084
- Email: arswamy@stanford.edu
Study Contact Backup
- Name: Kevin Flores
- Phone Number: 650-725-4796
- Email: kevinflo@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford Cancer Institute
-
Contact:
- Aneesh Swamy
- Phone Number: 650-725-2084
- Email: arswamy@stanford.edu
-
Contact:
- Kevin Flores
- Phone Number: 650-725-4796
- Email: kevinflo@stanford.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy volunteers age 18 or older
- Patients with a diagnosis of primary lung cancer or lung metastases of any primary tumor origin
- Patients deemed clinically eligible to be treated with standard of care lung SABR for patient arm
- Patients of any gender age 18 or older
- Patients with ECOG Performance Status 1-2 and select patients with Performance Status 3 deemed to be suitable candidates based on common sense clinical judgment on the risks versus benefits of SABR
Exclusion Criteria:
- No Pregnant Women
- Patients clinically deemed ineligible for standard of care lung SABR treatment for the patient arm (for example, excessive tumor size, severe pulmonary fibrosis are relative contraindications for lung SABR and are part of standard of care clinical decision making).
- Patients with newly-developed pneumothorax
- Patients with critical acute illness precluding SABR in the judgment of the treating physician (examples could include active pulmonary embolism and infection requiring inpatient care)
- Patients with ECOG Performance Status 4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Administration of Percussive ventilation breathhold (PVB) technique in healthy volunteers
The healthy patient will execute the Percussive ventilation breathhold technique
|
Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
|
Other: Administration of the PVB-SABR in lung cancer patients
Lung cancer patients will execute a PV breathhold and a verification cone-beam CT scan.
|
Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of successful Percussive Ventilation Breathhold (PVB) maneuver in healthy volunteers.
Time Frame: 18 months
|
The rate will be measured as the proportion of healthy volunteers who can be successfully execute the Percussive Ventilation Breathhold for 5 minutes.
In the event of a failure, both investigator and patient will be asked to specify the reason for failure for purposes of failure analysis.
|
18 months
|
Rate of successful administration of Percussive Ventilation Breathhold Stereotactic Ablative Radiotherapy (PVB SABR) in lung patients.
Time Frame: 18 months
|
The rate will be measured as the proportion of lung cancer patients who successfully complete treatment using the PVB SABR method as defined by 100% of the prescribed Stereotactic Ablative Radiotherapy dose being delivered using the Percussive Ventilation Breathhold (PVB) technique.
A failure will be defined as a patient who fails to use the method for any part of the treatment.
In the event of a failure, both investigator and patient will be asked to specify the reason for failure for purposes of failure analysis.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional time-related endpoints for duration of breathhold with Percussive Ventilation (PV) breathhold intervention for Healthy patients
Time Frame: 3 months
|
The rates will be measured as the proportion of healthy volunteers who can be successfully execute the PV breathhold for 10 minutes
|
3 months
|
Exploratory clinical and dosimetric data on Percussive Ventilation Breathhold Stereotactic Ablative Radiotherapy (PVB SABR) technique
Time Frame: 3 months
|
We will collect optional exploratory noninvasive clinical data during PVB including but not limited to real-time CO2 and SpO2 data (using the SenTec Digital Monitoring System or similar device) and surface anatomy monitoring (using devices such as Kinect camera, vision-RT, or laser surface monitoring system).
All of these data will be collected on an optional exploratory basis.
|
3 months
|
Questionnaire data on Hospital Anxiety and Depression for lung cancer patients
Time Frame: at baseline, and at the time of mock simulation (3 months)
|
Questionnaires on Hospital Anxiety and Depression Scale (HADS) will be collected on an optional exploratory basis at baseline and after the study intervention.
|
at baseline, and at the time of mock simulation (3 months)
|
Questionnaire data on patient anxiety for lung cancer patients
Time Frame: 8 weeks
|
Questionnaires on Spielberger State Anxiety (STAI) will be collected on an optional exploratory basis at baseline and after the study intervention.
|
8 weeks
|
Qualitative assessment of the training materials for Healthy patients
Time Frame: During first education session (8 weeks), then at the time of mock simulation (3 months)
|
qualitative questionnaire about the educational materials will be collected on an optional exploratory basis at baseline and after the study intervention.
|
During first education session (8 weeks), then at the time of mock simulation (3 months)
|
Qualitative assessment of the training materials for lung cancer patients
Time Frame: 8 weeks
|
qualitative questionnaire about the educational materials will be collected on an optional exploratory basis at baseline and after the study intervention.
|
8 weeks
|
Patient motivation to learn the technique from study educational materials for Healthy Patients
Time Frame: During first education session (8 weeks), then at the time of mock simulation (3 months)
|
learner motivation from the educational materials (LMSS) will be collected on an optional exploratory basis at baseline and after the study intervention.
|
During first education session (8 weeks), then at the time of mock simulation (3 months)
|
Patient motivation to learn the technique from study educational materials for lung cancer patients
Time Frame: 8 weeks
|
learner motivation from the educational materials (IMSS) will be collected on an optional exploratory basis at baseline and after the study intervention.
|
8 weeks
|
Additional time-related endpoints for duration of breathhold with Percussive Ventilation Breathhold (PVB) intervention for lung cancer patients
Time Frame: 3 months
|
The rates will be measured as the proportion of patients who can execute a PV breathhold for both 5 and 10 minutes
|
3 months
|
Exploratory clinical and dosimetric data on Percussive Ventilation Breathhold (PVB)
Time Frame: 3 months
|
We will collect optional exploratory noninvasive clinical data during PVB including but not limited to real-time CO2 and SpO2 data (using the SenTec Digital Monitoring System or similar device) and surface anatomy monitoring (using devices such as Kinect camera, vision-RT, or laser surface monitoring system).
All of these data will be collected on an optional exploratory basis.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Erik Blomain, MD, PHD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2022
Primary Completion (Estimated)
May 2, 2024
Study Completion (Estimated)
May 2, 2024
Study Registration Dates
First Submitted
February 24, 2022
First Submitted That Met QC Criteria
March 7, 2022
First Posted (Actual)
March 17, 2022
Study Record Updates
Last Update Posted (Actual)
August 24, 2023
Last Update Submitted That Met QC Criteria
August 22, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- IRB-63842
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States